EWM
IMVT icon

Evolution Wealth Management’s Immunovant IMVT Stock Holding History

Evolution Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$3.2K – 635
2025
Q2 		$3.2K Buy
+200
New +$3.02K ﹤0.01% 486

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Evolution Wealth Management's IMVT Position: Q3 2025 in Review

Evolution Wealth Management sold out of Immunovant (IMVT) in Q3 2025, closing a stake of 200 shares — an estimated $3.2K sold.

Evolution Wealth Management first reported a position in IMVT in Q2 2025 and held it in 1 quarter. The position peaked at $3.2K in Q2 2025. 186 funds tracked by Wall St. Rank hold IMVT as of Q3 2025.

  • Evolution Wealth Management reported no remaining Immunovant position as of Q3 2025 after selling out during the quarter.
  • Evolution Wealth Management sold 200 Immunovant shares in Q3 2025, an estimated $3.2K.
  • Evolution Wealth Management first reported a position in Immunovant in Q2 2025 and held it in 1 quarter.
  • Evolution Wealth Management's Immunovant position peaked at $3.2K in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q3 2025.

Based on Evolution Wealth Management's 13F filing for Q3 2025, filed 23 Oct 2025.